LOS ANGELES, CA / ACCESSWIRE / June 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / May 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
CVS Health (CVS) reported earnings 30 days ago. What's next for the stock?
Starbucks stock has been struggling as consumer demand continues to stall. Nike's brand remains popular with teens, but sales have underwhelmed of late.
CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CVS stock has plunged after reporting Q1 2024 results, presenting a potential buying opportunity due to its undervaluation. This stock now offers a 4.63% yield and CVS has built a unique ecosystem that makes it an attractive investment. Medicare Advantage presents a headwind for insurance companies in 2024, but this is a buying opportunity because it offers long-term growth potential.
LOS ANGELES, CA / ACCESSWIRE / May 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
CVS Health Corporation (NYSE:CVS ) Bernstein's 40th Annual Strategic Decisions Conference May 29, 2024 10:00 AM ET Company Participants Karen Lynch - President and CEO Tom Cowhey - Executive Vice President and Chief Financial Officer Conference Call Participants Lance Wilkes - Bernstein Lance Wilkes Okay. So we're going to kick-off.
CVS Health (NYSE: CVS) saw its net income expand by $4.2 billion or 101% y-o-y to $8.3 billion in 2023. This can primarily be attributed to the opioid litigation charges included in the 2022 results.
CVS Health provides a comprehensive suite of interrelated healthcare services. Gilead Sciences' sales are growing steadily, and newer approvals should help.
CVS Health Corp's share price has fallen, presenting an attractive entry opportunity with a current dividend yield of 4.8%. The risk profile includes slashed guidance and increased costs, but these issues are not unique to CVS and may be temporary. CVS has shown consistent dividend growth over time and has a potential upside of 28.5% based on average Wall St. price targets.
CVS has long been a reliable dividend payer. Despite management's recent guidance cut, it still has room to raise its dividend.